Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bauernfeind, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauernfeind, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. C, 77-82
© 1999 The British Society for Antimicrobial Chemotherapy

Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae

A. Bauernfeind*

Max. Von Pettenkofer-Institut, Pettenkoferstrasse 9a, D-80336 München, Germany

The aim of this study was to compare the bactericidal efficacy of levofloxacin and ofloxacin against Streptococcus pneumoniae at different dosage regimens for both agents. An in-vitro pharmacodynamic model was used. Levofloxacin kinetics of 500 mg, administered od or bd, were compared with ofloxacin kinetics of 400 mg od or bd. Killing by 3 log 10 (99.9%) was achieved up to an MIC of 0.5 mg/L (500 mg od) or 1 mg/L (500 mg bd). For levofloxacin killing of S. pneumoniae was unimpaired in mixed cultures with Haemophilus influenzae. For ofloxacin, killing by 2 log 10 was achieved up to an MIC of 0.5 mg/L for 400 mg od and up to an MIC of 1 mg/L for 400 mg bd. Killing by 3 log 10 was not achievable by 400 mg od, but was achieved up to an MIC of 0.5 mg/L for 400 mg bd. Killing of S. pneumoniae with identical MICs of levofloxacin was not influenced by their susceptibility to penicillin G. These data, together with the two-fold higher activity of levofloxacin in comparison with ofloxacin, indicate good therapeutic perspectives for levofloxacin over ofloxacin in the treatment of S. pneumoniae infections.

* Tel: +49-89-5160-5268; Fax: +49-89-5160-5266; E-mail: Adolf.Bauernfeind{at}mvp-bak.med.uni-muenchen.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.